Trade Schrödinger, Inc. - SDGR CFD

Schrödinger (SDGR) is a computational platform that facilitates the discovery of molecules for drug development and materials design for biopharmaceutical, academic institutions and government laboratories. 

Founded in 1990, Schrödinger is headquartered in New York. The company has customers and collaborators across more than 70 countries. Its collaborators include Agios Therapeutics, Ajax Therapeutics, Bright Angel Therapeutics, Eli Lilly and Company and Sanofi. 

Schrödinger specialises in oncology, antifungal, fibrosis, inflammatory bowel diseases, metabolic diseases, cardiopulmonary diseases, tuberculosis, neurodegenerative disease and more. 

MALT1 inhibitor is a key regulator of physiological antigen receptor signalling in B cells and T cells and are additive to covalent and non-covalent BTK inhibitors. The company announced US Food and Drug Administration (FDA) clearance of an investigational new drug application for SGR-1505, a MALT1 Inhibitor. 

Schrödinger leverages the software platform to advance its collaborative programmes and its novel therapeutics pipeline includes eight compounds that address unmet medical needs and are currently in the clinical development phase.

Schrödinger, Inc. stock began trading on the NASDAQ in 2020 under the ticker symbol SDGR. 

You can track live SDGR share value and price history at Capital.com.